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Abstract
Although surgical extirpation of tumors is usually clinically recommended, tumor removal may entail an undesired side effect: the risk 
of accelerating the growth of metastases. This effect may account for the relatively modest survival benefits observed when surgery 
is accomplished after tumor cells have already disseminated to distant anatomical sites even when tumor removal is combined with 
chemotherapy or immunotherapy. Although different mechanisms could contribute to the enhancement of residual tumor growth after 
tumor removal, probably a main effect is associated with the withdrawing of an inhibitory effect generated, by certain circumstances, by 
the primary tumor on its own metastases. This inhibitory effect is a particular case of a more general and paradoxical phenomenon known 
as concomitant tumor resistance (CR) in which a tumor-bearing host inhibits or retards the growth of secondary tumor implants despite 
the fact that the primary tumor grows progressively. In this essay we especially focus on the last investigations of our laboratory concerning 
the importance of tyrosine isomers as mediators of the phenomenon of CR and on their capacity to inhibit established metastases. Taking 
into account that metastases are considered the main problem in cancer pathology, our investigations aimed to elucidate the molecular 
basis of the phenomenon of CR might stimulate the design of new and less harmful means of managing malignant diseases, especially by 
controlling the growth of metastases after the removal of a primary tumor, or after other injuries or stressors that have been claimed to 
promote the escape of metastases from dormancy.
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The critical problem of metastases
Metastatic growth is considered a far more serious 
problem than the original tumor because, for most 
cases, they ultimately prove to be fatal for the patient. In 
effect, prior to metastases, most cancers could be cured 
surgically and 5-year survival rates are estimated at about 
90%. However, when a tumor has spread to different sites, 
those rates, even using some forms of systemic therapy 
(for example, chemotherapy or immunotherapy), often 
fall below 15% [1]. The true problem is that there is no 
assurance that an apparently localized cancer may be 
known “prior to metastases”. This means that a patient 
diagnosed with an apparently localized cancer has no 
guarantee that their tumor has not already spread. For 
example, in as many as one-third of patients diagnosed 
with localized breast cancer, carcinoma cells have already 
disseminated to distant anatomical sites at the time of 
initial diagnosis. However, these metastatic cells remain 
undiscovered by the current technics of detection until 
they awake and ultimately cause the death of the patients 
[2]. In other cases, the situation is worse. For example, 
more than 90% of patients with pancreatic cancer have 
already detected or undetected metastases at the time 
of initial diagnosis [3]. The management of cancer has 
improved since the declaration of “War against cancer” in 
1971. This improvement was partly due to early detection 
of the disease and partly due to better therapies. However, 
the progress has been, in most cases, much slower than 
originally expected, mainly associated with the difficulty of 
treating disseminated cancer [4, 5].
These considerations mean that the elucidation of 
mechanisms aimed to control the growth of metastases 
are of pivotal importance to design new and more efficient 
therapeutic strategies against cancer. In the following 
section we will consider some experimental and clinical 
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evidence that might help to unveil the nature of some of 
these mechanisms.
Tumor removal and growth of metastases
Experimental evidence
Accelerated growth of metastases following excision of the 
primary tumor was described more than a century ago by 
Tyzzer [6]. He observed that, although the surgical removal 
of a primary tumor prolonged the survival of mice, the 
size of the individual metastatic nodules was larger than 
in tumor-bearing mice. Similar results were obtained a 
decade later by Tadenuma and Okonogi [7] also working 
with murine models. In the last 90 years, these pioneering 
experiments were confirmed in many tumor models in 
which metastases were either detectable or undetected 
(occult metastases) at the time of tumor removal [8, 9].
As a whole, this large series of experiments can be summarized 
as follows:
When subcutaneous tumors were removed before the 
establishment of metastases, the surgery was curative. 
On the other hand, when metastases have already spread 
and settled in different tissues and organs, surgery failed 
to cure the animals and the outcome of that procedure 
was dependent on the size of the local tumor at the time of 
removal. Usually, when small tumors were concerned, the 
lungs and other organs were left with very few metastatic 
cells as compared with those in tumor-bearing animals 
in which the primary tumor continued to shed numerous 
cells into the circulation. In consequence, the total mass 
of proliferating metastatic cells in tumor-bearing animals 
exceeded the growth of the fewer cells existing in tumor-
excised animals. At this stage, tumor excision significantly 
prolonged the survival of the mice. When mid-sized tumors 
were removed, equilibrium could be reached between the 
enhanced effect on metastases exerted by the surgical 
extirpation of the primary tumor and the shedding of 
new potentially metastatic cells in tumor-bearing mice. In 
consequence, the total mass of proliferating metastatic 
cells was similar in both tumor-bearing and tumor-excised 
animals because although tumor-excised animals displayed 
fewer metastatic foci, each focus was of larger size. At this 
stage, tumor removal still, although modestly, prolonged 
the survival of the operated animals, presumably because 
even though both metastatic masses were similar, the 
presence of the primary growing tumor was deleterious 
for the health of the host. Finally, when large tumors were 
removed, a higher number and size of visible metastatic 
nodules than those present in tumor-bearing animals, were 
observed. This reflects the fact that, at that stage, tumor 
excision would promote the growth of visible metastatic 
foci as it would also induce non-visible ones to be large 
enough to be countable. In contrast, in the intact tumor-
bearing mice the growth of visible metastases would 
be limited and there would be no a growth-promoting 
stimulus for the emergence of new visible metastases 
from very small undetectable ones. At this stage, tumor 
excision resulted in a significantly reduced survival of the 
operated animals [8–17].
Clinical evidence
In clinical settings it is not easy to evaluate the impact of 
tumor removal on the kinetics of metastatic growth because 
surgery is one of the primary treatment modalities for solid 
tumors. In consequence, studies comparing metastatic 
growth in patients with non-excised tumors (expectant 
management) with those after tumor resection (surgical 
management) are very infrequent, although some of them 
are available in the literature. As a whole, these studies 
together with indirect evidence accumulated for the last 40 
years, suggest that the accelerated growth of metastases 
following excision of the primary tumor mentioned in the 
precedent section (see Experimental evidence) may also 
be associated with human cancer.
For example, Iversen [18] found no benefit with radical 
prostatectomy over expectant management for 
adenocarcinoma of the prostate in a follow-up study which 
followed 111 patients for 23 years.
Similarly, Demicheli [19, 20]; Retsky [21] and Desmedt [22] 
examined the death-specific hazard rates in patients with 
breast cancer that had undergone mastectomy alone with 
those of non-operated patients obtained from an accepted 
historical database. The non-operated patients (expectant 
management) exhibited a single peak between the fourth 
and the fifth year in the hazard rate for death. In contrast, 
a two peak hazard was detected in the operated patients: 
the first occurred between the third and the fourth year 
associated with metastases emerged rapidly between 6 
and 12 months after surgery followed by a second peak at 
the eighth year associated with metastases that emerged 
about 5-6 years after surgery. These experiments suggest 
that the natural history of breast cancer could, in some 
way, be adversely affected by removal of primary tumor, 
although its negative side effects are, in general, lower 
than its beneficial ones. In effect, up to date, the clinical 
studies showed that in most cases, tumor removal actually 
prolongs the survival of patients because the percentage 
of operated patients that died early (between the third 
and the fourth year after surgery) and late (eighth year) 
is significantly lower than that of non-operated patients. 
However, a recent debate concerning the utility of 
primary tumor removal in patients with breast cancer that 
present with distant metastases (stage IV) at diagnosis, 
has highlighted the problem in human cancer [23]. Up to 
date, the clinical studies directed to solve this controversy 
showed that tumor removal may improve the survival in 
patients with breast cancer with stage IV, but only in those 
displaying small primary tumors and limited metastatic 
load. When larger primary tumors and more metastatic 
load are concerned, surgery is not recommended [23].
Similar observations have been made concerning 
colorectal carcinomas. In effect, reported data from the 
literature support the view that primary tumor resection 
(PTR) in colorectal cancer with synchronous unresectable 
metastases should be discussed and validated by a phase 
III trial in selected patients exhibiting asymptomatic 
primary tumor, age ≤ 70 years, World Health Organization 
performance status (WHO-PS) < 2, no extra-hepatic 
metastatic disease and liver burden of less than 50%. In 
these patients, PTR, when performed laparoscopically 
and after preoperative immuno-nutrition, may lead to 
an increased overall survival. In all other cases, reported 
postoperative mortality and morbidity rates related to 
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PTR are high and up-front chemotherapy with the primary 
tumor left in place may represent the more reasonable 
option [24]. In another study, a total of 116 patients with 
synchronous colorectal liver metastases were identified of 
which 49 received an upfront primary tumor resection and 
67 received neo-adjuvant chemotherapy. The conclusion 
of this study indicated that tumor resection resulted in 
progressive disease suggesting that metastatic growth was 
enhanced after tumor removal [25].
In many other cancers, it has not been possible to directly 
evaluate the kinetics of metastatic growth after primary 
tumor removal because of the lack of control non-
operated patients. However, incidental but suggestive 
evidence has been reported. For example, Sugarbaker 
[26] reported a clinical case of a 26 year-old male with a 
melanoma in the scalp. The disease was clinically localized 
and evaluation revealed no disseminated metastases. 
A wide excision and graft was performed; six weeks 
after the operation, numerous subcutaneous nodules 
as well as visceral metastases appeared and the patient 
died shortly after. In the same way, partial spontaneous 
regression of a primary melanoma is actually considered 
a bad prognosis sign [12, 27]. Lange [28] reported a study 
of eight patients who underwent cytoreductive surgery 
for testicular cancer; in each case, the surgical procedure 
led to a very faster growth of regional and distant residual 
disease than that expected by assuming an uninterrupted 
natural growth of these residual tumors. Similar findings 
in patients with epithelial ovarian cancer [29] led to some 
investigators to urge caution with respect to cytoreductive 
surgery. The above clinical studies, together with similar 
investigations carried out with patients affected by similar 
or other malignancies strongly suggest that acceleration 
of metastatic growth may be the undesired outcome of 
surgical removal of many common human cancers such as 
melanomas, osteosarcomas and breast, testicular, ovarian, 
lung, colorectal and bladder carcinomas [8, 12, 30, 31].
Mechanisms associated with the early acceleration 
of metastases upon tumor removal
As a whole, the above mentioned experimental and clinical 
results are in agreement with the fact that the removal of 
a tumor in animals or human beings prolonged, in most 
cases, their survival, especially when the tumors are not 
large and metastatic load is not high. An obvious advantage 
of surgical treatment is the reduction of levels of circulating 
tumor cells released by the tumor, which can be seeded 
as metastatic foci. In addition, surgical resection can 
reduce different symptoms including pain, ulceration and 
lymphoedema that may adversely impact quality of life and 
function and can also reduce potential immunosuppressive 
factors released by the primary tumor that may affect 
putative anti-tumor immune responses. However, on the 
other hand, a putative disadvantage of surgery is based on 
the fact that it can promote the progression of metastases. 
In consequence, we suggest that coupling surgery with 
treatments aimed to restrain metastatic growth after 
surgery might, significantly improve the current survival of 
cancer patients.
Some metastases seem to emerge rapidly or relatively 
rapid after surgery. Others appear after a long time - 
some months in mice and many years in humans - after 
tumor removal. Herein, we will discuss only the putative 
mechanisms underlying the rapid emergence of metastases 
after surgical tumor excision because they are supposedly 
more related to the process of tumor withdrawing. On 
the other hand, the late emergence of metastases or 
residual tumors may probably be associated with other 
explanations that have been accounted by our group and 
others elsewhere [5, 32–34].
The mechanisms claimed to underlie the rapid emergence 
of metastases after surgical tumor excision may broadly be 
divided into two groups: A) The presence of a primary tumor 
does not exert any inhibitory influence on metastases and 
enhancement of metastatic growth after tumor removal 
is an emergent phenomenon associated with the injury 
related to the withdrawing of the tumor; B) The presence 
of a primary tumor exerts an inhibitory or growth-retarding 
effect on metastases and enhancement of metastatic 
growth after tumor removal is only the consequence of the 
withdrawing of that inhibitory influence.
A) A relatively simple mechanism through which surgery 
could trigger early metastatic relapse was suggested more 
than 20 years ago and may derive from the release of 
cancer cells from the surgical bed during the process of 
resection [35].
More recently, it has been claimed that surgery up-regulates 
adhesion molecules in target organs, recruits immune cells 
capable of entrapping tumor cells and induces changes in 
cancer cells themselves to enhance migration and invasion 
to establish at the target site [36].
In addition, surgical trauma induces local and systemic 
inflammatory responses that can also contribute to the 
accelerated growth of residual and micro-metastatic 
disease [36]. Recently, Krall [2] suggested that the systemic 
inflammatory response induced after surgery associated 
with the post-surgical wound-healing response promoted 
the emergence of metastases whose growth was otherwise 
restricted by a tumor-specific immune T-cell response. In 
support of this contention, these authors demonstrated 
that peri-operative anti-inflammatory treatment 
significantly reduced tumor outgrowth in their model 
but only when the experiments were carried out with an 
artificially-induced strongly immunogenic tumor growing in 
immune-competent mice but not in immune-incompetent 
NOD/Scid mice. These results are in agreement with 
previous clinical studies that demonstrated that some anti-
inflammatory analgesics – in particular the non-steroidal 
anti-inflammatory ketorolac – reduced the incidence of 
early metastatic recurrence in breast cancer patients 
[22, 37]. It is worth to note, however, that there are some 
doubts with this interpretation since treatment with other 
non-steroidal anti-inflammatory agents – for example 
diclofenac – did not produce such anti-metastatic effect 
[22]. In fact, Guo [38] suggested that the anti-metastatic 
effects of ketorolac could be attributed to its ability to 
diminish tumor cell adhesion, migration and invasion 
rather than to its anti-inflammatory properties.
B) Although the mechanisms mentioned in item A) could 
contribute to the enhancement of residual tumor growth 
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after tumor removal in some experimental and human 
tumors, they probably do not represent the whole story. 
In effect, in a number of experiments carried out for many 
years, control series were included that demonstrated that 
accelerated growth of metastases following tumor excision 
was not due or was not mainly due to high release of tumor 
cells, stress, surgical trauma or anesthesia. This conclusion 
is supported by three kinds of experiments: First, sham 
operations including surgical procedures carried out in the 
local area without removing the tumors, or amputation of 
a non-tumor bearing leg leaving intact the tumor in the 
other leg, had no influence on the metastatic growth [9, 11, 
17, 39–41]. Second, accelerated metastatic growth after 
tumor extirpation can be abrogated by re-inoculation of 
cells of the removed tumor. This abrogation was achieved 
when high doses of tumor cells were re-inoculated and 
local tumor reached the size at which the inhibitory effect 
putatively exerted or induced by the tumor was fully 
expressed. On the other hand, re-inoculation of small 
doses of tumor cells had no influence on the growth of 
metastases, presumably because the latent period for 
tumors was too long to influence the growth of metastatic 
cells already settled in lung or elsewhere [9, 13, 42]. Third, 
experimental secondary tumor implants carried out by 
the subcutaneous, intravenous or intra-peritoneal routes 
were strikingly inhibited by the presence of a primary 
tumor in both immune-competent and immune-deficient 
mice. In these experiments, either immunogenic or non-
immunogenic murine tumors, as well as human tumors 
growing in immune-deficient mice were used. These 
experiments suggested that a primary tumor can restrain 
the growth of metastases that can be considered as natural 
secondary tumor implants developed spontaneously during 
the growth of a primary tumor [9, 15, 16, 42–49]. These 
experiments also demonstrated that the mechanisms of 
enhancement of metastases after tumor removal would 
not be necessarily dependent upon a previous immune 
restriction of the metastatic foci because the inhibition 
produced by the primary tumor on its metastases can be 
immunological, as well as non-immunological in nature.
The phenomenon of concomitant tumor resistance
Taken together, the available evidence suggests that, 
although other mechanisms may affect the fate of 
metastases after the removal of a primary tumor, probably 
a main effect is associated with the withdrawing of an 
inhibitory effect generated, upon certain circumstances, by 
the primary tumor on its own metastases. This inhibitory 
effect is a particular case of a more general phenomenon 
known as concomitant tumor resistance. Concomitant 
tumor resistance or, more briefly, concomitant resistance 
(CR) is the paradoxical phenomenon according to which 
a tumor-bearing host inhibits or retards the growth 
of secondary tumor implants despite the fact that the 
primary tumor grows progressively [12, 50]. CR was 
originally described by Paul Ehrlich at the turn of the 20th 
century [51] but, apart from a few isolated reports [52, 53] 
it remained virtually forgotten for about 60 years until it 
was re-discovered in the 60’s by Southam [54], Gershon 
[55] and others [56, 57]. Since that moment on, some 
groups have studied this phenomenon demonstrating that 
both immunogenic and non-immunogenic tumors can 
induce CR in different animal models such as mice, rats 
and hamsters [9, 16, 17, 45, 58, 59]. However, even after 
its renascence, CR has not received much attention as 
compared with other areas of cancer research despite the 
fact that it has been directly described in human beings 
[54] and, as shown above, despite its putative relevance to 
the mechanisms of metastases control. At first sight, this 
lack of attention in the phenomenon of CR may be related 
to the fact that its study implies the search for anti-tumor 
mechanisms that depend on the presence of a primary 
growing tumor. This apparently paradoxical approach 
does not seem to have been attractive and promissory for 
many.
Although the phenomenon of CR against the growth of 
metastases has been observed in many experimental 
systems and it has also been suspected in many clinical 
situations, on the other hand, there are also some 
experimental and clinical evidence that the presence of a 
tumor may not exert any effect or even a stimulating effect 
(Concomitant enhancement, CE) on their metastases 
[60–64]. In such cases, tumor removal would not induce 
any acceleration or even it would induce an inhibition 
of metastatic growth. In clinical settings, few putative 
examples of CE have been reported. Most of them have 
been related to occasional suspected regressions of hepatic 
and/or pulmonary metastases following nephrectomy 
for renal cell carcinoma [65–68]. In our laboratory, we 
have demonstrated the presence of both CR and CE 
phenomena in some tumor-bearing mice, depending on 
the ratio between the mass of the larger primary tumor 
mass relative to that of the smaller secondary one, with 
high ratios rendering inhibition and low ratios inducing 
stimulation of the secondary tumor. However, in our 
experience, the magnitude of this stimulatory effect, 
whenever it is present, proved to be rather modest as 
compared with the magnitude of the inhibitory effect [69]. 
A similar conclusion may be attained by analyzing the data 
from other laboratories [47, 64].
In consequence, taken together, the available experimental 
and clinical evidence suggest to us that CR would be more 
likely than CE to govern the behavior of animal as well as 
commonly occurring human tumors.
Mechanisms associated with the phenomenon of 
concomitant tumor resistance
Historical background
Different hypothesis have been proposed to explain the 
phenomenon of CR
According to the immunological hypothesis, the growth of 
a tumor generates a specific antitumor immune response 
which even though it is not strong enough to inhibit the 
primary tumor growth, is still capable of preventing 
the development of a relatively small secondary tumor 
inoculum. This explanation is not very different from that 
of conventional immunological rejection of allogeneic 
tumors in naive mice or immunogenic syngeneic tumors 
in pre-immunized animals. The immunological hypothesis 
was originally proposed by Bashford [52] which, in turn, 
coined the term “concomitant immunity” by which this 
phenomenon has been known in the past.
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This interpretation is supported by solid evidence mainly 
based on experiments with strongly immunogenic murine 
tumors induced by chemical agents or viruses [59, 70]. 
However, it does not provide a satisfactory explanation 
for the fact that CR has also been observed in association 
with spontaneous murine tumors of non-detectable 
immunogenicity [16, 17, 58, 59].
Non-immunological explanations rely mainly on two 
hypotheses
Ehrlich [51] and Tyzzer [6] believed that nutrients essential 
for tumor growth are consumed by the primary tumor, 
making it difficult or impossible for a second implant 
to develop (atrepsis theory). The term “atrepsis” was 
coined by Joseph Parrot in 1874 to describe malnutrition, 
especially in infants [71]. A support for the atrepsis theory 
to explain CR is associated with the fact that a progressive 
tumor is a trap for glucose, nitrogen and other nutrients. 
In this way, all attempts to correct the weight loss in tumor-
bearing organisms by supplying different nutrients by the 
intravenous route resulted in acceleration of tumor growth 
[9]. Taking into account that there is convincing evidence 
that restriction of nutrients may be accompanied by 
inhibition of tumor growth, it is possible that in the setting 
of a severe systemic biochemical disturbance generated 
by the primary tumor, the condition for the proliferation 
of re-inoculated tumor cells (secondary tumor implants) 
cannot be as favorable as in control animals.
Others [9, 48, 72–74] have postulated that the primary 
tumor produces or induces the production of anti-
proliferative nonspecific substances or anti-angiogenic 
molecules which limit the replication of tumor cells of the 
second inoculum. The idea that a tumor induces systemic 
effects by the production of some kind of substances was 
originally suggested by Nakahara and Fukuoka in the 50’s 
in their concept of cancer toxohormone, whose circulating 
concentration should rise with increased tumor mass 
[75].
Taken together, these non-immunological hypotheses can 
offer a putative explanation for the CR induced by non-
immunogenic tumors but not for the specific inhibition of 
secondary tumor implants observed during the growth of 
immunogenic tumors.
The two main peaks of CR throughout tumor growth
For the last 30 years, we have studied, in our laboratory, 
the phenomenon of CR associated with the growth of 
many murine and human tumors (the latter growing into 
immune-deficient mice) in an attempt to integrate the 
different hypotheses into a coherent picture. Our results, 
summarized in Table 1 and reported, at least in part, in 
former papers [17, 45, 49, 59, 73, 76, 77] demonstrated 
that, two main temporally separate peaks or events of CR 
are generated during primary tumor growth. The first peak 
was only induced by immunogenic tumors of small size (≤ 
500 mm3); it was tumor-specific and thymus-dependent 
as it was exhibited in euthymic but not in nude mice, its 
intensity was proportional to tumor immunogenicity and a 
typical immunological rejection - associated with extensive 
necrosis and a profuse infiltration with polymorphonuclear 
granulocytes and mononuclear cells was observed 
histologically at the site of the second tumor implant 
undergoing CR. Furthermore, the kinetics of appearance 
and disappearance of the first peak of CR paralleled the 
kinetics of appearance and disappearance of specific 
cytotoxic antibodies and cell-mediated cytotoxicity against 
the tumors.
On the other hand, the second peak of CR was induced 
by both immunogenic and non-immunogenic large tumors 
(≥ 2000 mm3); it was tumor-non-specific and thymus-
independent as it was exhibited in both euthymic and 
nude mice, it did not correlate with tumor immunogenicity 
and its intensity was proportional to the primary tumor 
mass: the larger the primary tumor, the stronger the 
inhibition of the secondary tumor. Further, the inhibition 
of the secondary tumor by a large primary tumor was 
neither associated with a massive or focal necrosis nor 
with any host cell infiltration, contrasting with a classical 
immunological rejection. Instead, the secondary tumor 
implant remained in a dormant-like state, with viable but 
non-infiltrating tumor cells placed at the inoculation site 
between the skin and the muscular layer. Occasionally 
some apoptotic tumor cells began to appear after 24 h of 
inhibition.
Some years ago, an intermediate peak of CR was reported 
to be associated with a particular type of mid-sized tumors 
(1,000 - 1,500 mm3) – typically the Lewis lung carcinoma 
that restrain secondary tumors indirectly, by limiting 
tumor neovascularization [72]. Although the mechanisms 
associated with the first and intermediate peaks of CR 
have been elucidated as T cell–dependent and angiostatin-
dependent, respectively, the molecular basis of the most 
universal manifestation of CR, that is, the second peak, 
remained an enigma for many years.
In former studies, we demonstrated that the intensity of the 
second peak of CR correlated with the activity of a serum 
factor (or factors), different from antibodies, complement 
or other well characterized growth inhibitory molecules, 
that inhibited the in vitro and in vivo proliferation of 
tumor cells. Further, mice bearing tumors that produced 
CR and such inhibitory serum factors, could have or not 
have metastases, but in the case of having detectable or 
undetectable metastases, metastatic growth was strongly 
enhanced after tumor removal. Reciprocally, when the 
serum inhibitory activity was absent – the only two cases 
were mice bearing two highly metastatic mammary 
carcinomas – the second peak of CR did not appear [13, 
15, 59]. Further, after surgical extirpation of these tumors, 
growth of metastases was not stimulated.
These results suggested a direct correlation among the 
second peak of CR, the capacity to restrain the growth 
of metastases and the titer of serum growth inhibitory 
activity. Very interestingly, metastases produced by the 
two tumors that did not produce CR, were significantly 
inhibited by both the concomitant presence of unrelated 
tumors that induced CR and by the daily administration of 
serum from mice bearing these unrelated tumors, which 
displayed a high titer of growth inhibitory activity.
In recently published works [17, 45], we identified the anti-
tumor serum factors associated with CR as a rather equi-
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molar mixture of meta-tyrosine (m-Tyr) and ortho-tyrosine 
(o-tyr), two unnatural isomers of tyrosine, unnatural 
meaning that it is thought that they are absent from normal 
proteins [78, 79]. We carried out this characterization 
starting from mice bearing a non-immunogenic murine 
lymphoma that produces the strongest second peak of CR 
among all our murine tumor models [17] and also from 
nude mice bearing a human prostatic carcinoma that 
produces the strongest CR among all the human lines 
tested [45]. We could demonstrate that m-tyr and o-tyr 
were responsible for 90% and 10%, of the total antitumor 
activity of the serum, respectively, as determined by the 
inhibition of both the in vitro proliferation of different 
murine and human tumor cells and the in vivo growth of 
subcutaneous tumor implants.
Table 1 Origin, level of immunogenicity and intensity of concomitant tumor resistance induced by 20 murine tumors of different histological type and three 
human tumor lines growing in nude mice.
Tumor Origin Immunogenicity
Concomitant tumor resistance
1º Peak 2ª Peak
Murine
L15-A1 Allogeneic Very strong Very high Very high
MC-D2 Induced by MCa Very strong Very high Moderate
MC-C2 Induced by MCa Very strong High High
MNU-MPA3 Induced by MNU-MPAb Moderate Moderate Moderate
MC-B2 Induced by MCa Moderate Moderate Moderate
S-180-O2 Spontaneous Moderate Moderate Moderate
MNU3 Induced by MNUc Weak Low Moderate
M33 Spontaneous Weak Low Moderate
LMM33 Spontaneous Weak Low Absent
CS3 Induced by MMTVd Weak Low High
C7HI3 Induced by MPAe Undetectable Absent Absent
PX2 Induced by GCf Undetectable Absent Moderate
S-180-N2 Spontaneous Undetectable Absent Moderate
P3881 Induced by MCa Undetectable Absent Very high
CM3 Spontaneous Undetectable Absent High
CEP3 Spontaneous Undetectable Absent High
CEI3 Spontaneous Undetectable Absent High
CPV3 Spontaneous Undetectable Absent Moderate
L15-S1 Spontaneous Undetectable Absent High
LB1 Spontaneous Undetectable Absent Very high
Human
KBα Spontaneous ----------- Absent High
Calu-6β Spontaneous ----------- Absent High
PC3γ Spontaneous ----------- Absent Very high
Abbreviations: 1Lymphoma-leukemia; 2Fibrosarcoma; 3Carcinoma; aMC = Methylcholanthrene; bMNU-MPA = N-methyl-N-nitrosourea + medroxyprogesterone 
acetate; cMNU = N-methyl-N-nitrosourea; dMMTV = Murine mammary tumor virus; eMPA = medroxyprogesterone acetate; fGC = glass cylinder; 
αNasopharyngeal carcinoma; βLung carcinoma; γProstatic carcinoma. More details of the tumors are given elsewhere: see quotations [8, 12, 13, 15-17, 45, 49, 
59, 76, 77].
Therapeutic effect of m-tyr and o-tyr on established 
metastases of murine and human origin
The first evidence of the therapeutic value of m-tyr and 
o-tyr on established metastases was obtained using mice 
bearing two different murine metastatic mammary tumors 
growing subcutaneously. These tumors did not produce 
CR against experimental secondary tumor implants but 
they were very sensitive to the CR induced by unrelated 
tumors. When a periodic treatment of these tumor-bearing 
mice with m-tyr or o-tyr was initiated at the time when 
metastatic foci were already present in both lung and liver 
as demonstrated in control sacrificed tumor-bearing mice 
- a striking inhibition of metastatic growth was observed as 
evaluated in tumor-bearing mice that were sacrificed three 
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and four weeks after the onset of the treatment [45, 49, 
80, 81].
Similar results were observed on human metastatic cells 
growing in immune deficient mice [45, 49]. In one series 
of experiments, the inhibitory effect of m-tyr was achieved 
against experimental metastases produced in the lung 
by the intravenous inoculation of cells from a human 
prostatic tumor line; the rationale to use experimental 
metastases was due to the fact that this human tumor line 
growing subcutaneously does not produce metastases 
spontaneously neither in nude nor in NOD/Scid gamma 
mice. In another series of experiment, using a human 
breast carcinoma that produces metastases spontaneously 
in NOD/Scid gamma mice, periodic treatment with m-tyr 
resulted in a significant inhibition of spontaneous lung 
metastases as evaluated in mice that were sacrificed 3 
weeks after the onset of the treatment.
The most impressive evidence of the therapeutic value 
of m-tyr and o-tyr was obtained in an experiment aimed 
to mimic a putative clinical situation. A highly metastatic 
mammary murine tumor - called LMM3 - was surgically 
removed at the time when metastases had already settled 
in lung and liver. Then, a daily inoculation of either m-tyr 
or o-tyr by the intravenous route was carried out for 35 
consecutive days starting one day after surgery. The 
results revealed a striking anti-metastatic effect produced 
by both tyrosine isomers although the effect produced 
by m-tyr was significantly more robust than that of o-tyr. 
In effect, all controls (9 out of 9) died rapidly (median of 
survival = 29 days after surgery), exhibiting high number 
of lung and hepatic metastases. In contrast, only two m-tyr 
treated-mice died (at days 29 and 97 after surgery), while 
the other 6 mice remained alive without exhibiting signs 
of local or metastatic disease for the rest of their lives: 
when these mice were sacrificed at 22 months old (that 
is about 18 months after the end of the treatment) no 
metastatic foci were detected neither in lung nor in liver 
nor elsewhere. As for o-tyr treated mice, all mice (5 out of 
5) died although significantly later (median of survival = 80 
days after surgery) than controls [49, 80]. For illustrative 
purposes of this experiment, we show the Figure 1 that 
has already been published by our group in Strazza [49].
When treatment with m-tyr was initiated later, when the 
metastatic load were three times larger than in the first 
experiment, a significant anti-metastatic effect was also 
achieved and a significant percentage of treated mice 
(50%) survived at least six months after all controls had 
died [45].
The therapeutic value of these and similar experiments 
is stressed by the fact that the striking antitumor effects 
mediated by m-tyr and o-tyr were observed without 
exhibiting any detectable toxic-side effects even using 
doses 20 times higher than therapeutic ones [45, 49, 80].
Origin of tyrosine isomers and putative mechanisms 
of tumor inhibition
To date, m-tyr and o-tyr have been studied almost 
exclusively as markers for oxidative damage associated 
with abnormal proteins as detected in, for example, the 
blood of animals subjected to cardiac ischemia-reperfusion 
injury, mitochondria of exercised animals, atherosclerotic 
tissue of diabetic primates, and aging lens of humans [79]. 
Most investigators have assumed that m-tyr and o-tyr are 
generated post-translationally when the L-phenylalanine 
present in proteins is exposed to hydroxyl radicals during 
oxidative damage. However, it was recently suggested that 
oxidized amino acids, such as m-tyr and o-tyr, may also be 
generated from free amino acids that subsequently could 
be incorporated into proteins during synthesis [78, 79].
In previous experiments [17], we observed that the 
serum antitumor activity attributed to m-tyr and o-tyr was 
strongly inhibited by agents that reduced the number of 
myeloid-derived suppressor cells (MDSC) and oxidative 
damage, and that in many tumor-bearing mice and some 
cancer patients, MDSCs that produced large amounts of 
reactive oxygen species accumulated progressively in 
circulation [17, 82–85]. On the basis of these results, we 
suggested that free m-tyr and o-tyr present in the serum 
from tumor-bearing mice will be produced, at least in part, 
when circulating molecules of phenylalanine are oxidized 
by hydroxyl radicals released by MDSC.
The inhibition exerted by m-tyr and o-tyr on tumor growth 
mimics the inhibition produced by CR. In both cases, tumor 
inhibition was primarily associated with the presence of a 
high proportion of tumor cells in G0, a decrease in G2-M 
phases, and an increase or accumulation of cells in the 
S-phase, considered the consequence of an S phase arrest 
[17]. Further, the inhibitory effect produced in vitro and 
in vivo by m-tyr and o-tyr on tumor cell proliferation was 
counteracted by phenylalanine and, to a lesser degree, by 
glutamic acid, aspartic acid, glutamine and histidine, but 
not by tyrosine or the remaining protein amino acids.
Figure 1 Percent survival of mice after surgical excision of LMM3 tumors. 
The experiment can be summarized as follows: Twenty-eight (28) mice were 
inoculated s.c. with 2 × 105 LMM3 tumor cells (LMM3 is a highly metastatic 
murine mammary adenocarcinoma of spontaneous origin [45, 49, 80]). 
Eighteen days later 22 tumor-bearing mice were surgically operated to 
remove the tumor and the remaining 6 were sacrificed to evaluate the 
number of lung metastases at the time of surgery (mean [range] = 6 [3-10]). 
Then, the tumor-excised mice were divided into three groups. One group 
(n = 8) received, for the following consecutive 35 days, a daily i.v. injection 
of m-tyr (67 mg/kg). The second group (n = 5) received, for the following 
consecutive 35 days, a daily i.v. injection of o-tyr (67 mg/kg). The third group 
(n = 9) received saline (control). The Figure shows the percentage of the 
survivors of m-tyr-treated, o-tyr-treated and control mice (ordinate) as 
a function of the days after surgery (abscissa). The surgical excision was 
very satisfactory since no tumor relapsed. Death of mice was associated 
with lung and hepatic metastases. *: Difference between o-tyr-treated and 
control was p < 0.02; **: Difference between m-tyr-treated and control was 
p < 0.002; Log Rank test.
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A molecular analysis [17, 45] showed that the antitumor 
effects mediated by m-tyr and o-tyr on murine and human 
tumor cells were mediated, at least in part, by an early 
inactivation of p-STAT3 and down regulation of the NFκB//
NOTCH axis that are constitutively activated in many 
tumor cells. Inactivation of STAT3 impaired its nuclear 
translocation and down regulated the expression of survivin 
as well as other genes engaged with cell proliferation and 
survival that are targets of STAT3, such as BCL-XL (B-cell 
lymphoma XL), cyclin D1 and myc, among others. Taken 
together, all of these effects could drive tumor cells into a 
state of dormancy in G0 phase as determined by the low 
expression of Ki167 protein in tumor cells treated with 
tyrosine isomers. On the other hand, the S-phase arrest 
might be generated by a different mechanism that up to 
date, remains speculative. Several factors and conditions 
such as resveratrol, hyperoxia, hydroxyurea, ultraviolet 
radiation, G-rich oligonucleotides and zidovudine, 
induce the inhibition of cell proliferation associated with 
an S-phase arrest, presumably by the activation of an 
intra–S-phase checkpoint [86]. Different mechanisms for 
activating this checkpoint have been proposed, including 
accumulation of cdk2 (cyclin-dependent kinase 2) in its 
inactive phosphorylated form, downregulation of cdk2, 
activation of ATM/ATR (ataxia telangiectasia mutated/
ataxia telangiectasia Rad 3-related) kinase in response 
to DNA damage, modulation or inhibition of a replicative 
helicase activity, and downregulation of cyclin A2.
After these primary effects, apoptosis and autophagy were 
observed in some of the previously arrested tumor cells. 
Putative mechanisms of activation of autophagy by m-tyr 
have been studied in our last paper [45]. Previous reports 
have shown that STAT3 inhibition, such as produced 
by m-tyr, induces signs of autophagy [87]. Alternatively, 
m-tyr may be incorporated into eukaryotic proteins via a 
specific tRNA-dependent pathway, using mitochondrial 
and possibly cytosolic phenylalanyl-tRNA synthetase [88]. 
In turn, elevated m-tyr content in proteins may lead to the 
dysfunction of intracellular signaling such as the inhibition 
of LC3-II degradation [89] observed in our experiments, 
which promotes the activation of autophagy [45].
The central paradox of concomitant tumor 
resistance
The central paradox of CR, i.e., the inhibition of secondary 
tumor implants together with the progressive growth of 
the primary tumor, has remained unresolved for more 
than a century. To account for this problem, we showed 
that as a primary tumor grew subcutaneously, relatively 
large amounts of most amino acids, including those that 
counteract the inhibitory effects of m-tyr and o-tyr (i.e., 
phenylalanine, glutamic acid, aspartic acid, glutamine and 
histidine), accumulated in the tumor microenvironment, 
whereas at a contralateral flank receiving a secondary 
tumor implant, the content of amino acids was significantly 
lower. Furthermore, a cocktail of amino acids similar 
to that detected close to the primary site proved to be 
more counteracting of the antitumor effects produced by 
m-tyr and o-tyr than a cocktail similar to that detected at 
the secondary site [17]. On this basis, we suggested that 
a secondary tumor can be inhibited by circulating m-tyr 
and o-tyr, while at the same time, the primary tumor is 
protected from their inhibitory effects, at least in part, by 
these counteracting amino acids and thus can continue 
to grow [17]. This suggestion seems to reconcile the two 
major non-immunological interpretations of CR that have 
been advanced to date, i.e., the anti-proliferative-factors 
hypothesis and the atrepsis theory [9, 51, 72–74]. In effect, 
the postulation that serum m-tyr and o-tyr are responsible 
for the inhibitory effect generated by a primary tumor on 
the growth of secondary tumor implants is similar to the 
hypothesis of anti-proliferative factors. However, the mere 
presence of inhibitory factors such as m-tyr and o-tyr is not 
enough to explain why the primary tumor can grow while 
the secondary one cannot. On the other hand, the different 
concentration of amino acids at the site of the primary 
tumor compared with that at the site of a secondary tumor 
implant would appear to support the atrepsis theory 
because, according to this theory, the primary tumor 
accumulates elements that allow it to grow and whose 
lack at distant sites from the primary tumor will prevent a 
second tumor from growing. However, whereas according 
to the atrepsis theory, these elements are nutrients that 
would directly stimulate growth of the primary tumor, in 
our postulation, these elements would allow the primary 
tumor to grow by counteracting the effect of circulating 
inhibitory factors. Some years ago, Prehn [50] anticipated 
this interpretation and suggested that CR could best be 
explained by the competitive interaction of two opposing 
- and up to that time uncharacterized - influences: a local, 
slowly diffusible, tumor-facilitating environment that 
would be counteracted by circulating inhibitors.
This interpretation might also explain two intriguing 
questions associated with the biological effects of m-tyr 
and o-tyr. Data from our and other laboratories suggest 
that both tyrosine isomers can inhibit not only the in vitro 
proliferation of tumor cells but also, although probably to 
a lesser extent, that of normal cells [17, 78, 79]. However, a) 
the regeneration of normal tissues is usually not affected 
in tumor-bearing mice that exhibit CR [48, 90], and b) 
periodic inoculation of m-tyr and o-tyr, that produces a 
strong inhibition on the growth of metastatic foci, at the 
same time it does not produce any inhibitory effect neither 
on normal regenerative processes, development of normal 
immune responses nor on proliferation in vivo of MDSC that, 
at least in part, would produce m-tyr and o-tyr in tumor-
bearing mice [45, 49]. We could explain these questions 
by assuming that these normal proliferating tissues, but 
not secondary tumor implants, display a content of amino 
acids high enough to counteract the inhibitory effects 
produced by m-tyr and o-tyr. Experiments underway in our 
laboratory are aimed to confirm these assumptions.
New avenues for cancer understanding and 
treatment
Surgical extirpation is the mainstay treatment of solid 
tumors and may be curative when metastatic cells have 
not already disseminated from the primary tumor [1]. 
However, although it is recommended in most clinical 
cases, tumor removal may entail an undesired side effect 
i.e., the acceleration of regional and distant (metastases) 
residual neoplastic disease [36]. This effect may account 
for the disappointingly modest survival benefits observed 
when surgery is accomplished when tumor cells have 
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already disseminated to distant anatomical sites even 
when tumor removal is combined with systemic treatments 
such as chemotherapy. Investigators have proposed 
some therapeutic options to limit metastatic growth after 
tumor removal, including the use of perioperative (instead 
of postoperative) chemotherapy, antioxidant agents, 
immunotherapy, and bio-modulation [91], but to date, the 
results have not been as promissory as expected.
The elucidation of the phenomenon of CR could contribute 
to overcome this problem on the basis that the mechanisms 
underlying CR can be considered similar or identical to 
those utilized for a primary tumor to limit the growth of its 
own natural secondary tumor implants generically known 
as ‘metastases’.
However, in the past, CR has usually been rather neglected 
by researchers and clinicians. As we stated above (see 
the section called “The phenomenon of concomitant 
tumor resistance”) this attitude could, at first sight, be 
due to the fact that the study of CR does not seem to be 
attractive since it implies to search for mechanisms of 
tumor inhibition that depend on the presence of a primary 
growing tumor. Probably, the root of this attitude is more 
profound. In effect, the idea that a primary tumor may 
exert inhibitory influences upon distant metastases meant 
that a tumor had to be considered an integrated, organ-
like entity rather than a collection of independent atypical 
cells as it has been usually considered.
However, there are numerous observations in the 
literature that support that idea [5, 19, 32, 50, 73, 92–
95]. For example, hepatectomy stimulates mitosis in 
previously resting hepatocytes that had been implanted 
ectopically, or nephrectomy stimulates the proliferation 
(and also the hypertrophy) of the contralateral kidney in 
the same way that excision of a primary tumor induces 
mitosis in previously arrested secondary tumor implants. 
Furthermore, different from bacteria and other unicellular 
organisms which grow exponentially, if nutrients are 
available, growth of both normal organs and tumors follow 
a Gompertzian-like curve that is exponential at first and 
then it is modified by an exponential decline in rate when 
they approach to an asymptote. This decline proved not to 
be caused by failure of blood and nutrients supply or any 
other artifact of increased size. The only difference between 
a normal organ and a tumor, apart from the tendency of 
a tumor to metastasize, seems to be that the plateau size 
of the normal organ is reached when the organ reaches 
its full size, while the putative plateau size of the tumor 
would be larger than is compatible with the life of the host 
[96]. In addition, it has been demonstrated in different 
murine tumors, that mixtures of particular sub-clones 
tended, in the resulting tumors, to approach reproducible 
proportions characteristic for that array of sub-clones 
and that these final proportions were independent of the 
starting proportions and of the selective pressures favoring 
each particular sub-clone [96]. This could hardly have been 
possible if each particular sub-clone were not in some type 
of communication with the other sub-clones in order to 
maintain them in a constant proportion despite different 
selective pressures.
In a relatively recent paper [17] we have elucidated 
the serum factors responsible for the most universal 
manifestation of CR, as a mixture of m-tyr and o-tyr, 
two unnatural isomers of tyrosine that exhibited strong 
antitumor effects. In subsequent communications [45, 49, 
80, 81], we could demonstrate that both m-tyr and o-tyr 
could inhibit, in both in vitro and in vivo settings, not only 
the proliferation of tumor cells derived from tumors that do 
induce CR, but also that of those derived from tumors that 
do not induce CR, thus widely increasing their therapeutic 
possibilities.
The most anti-tumor impressive effect of both tyrosine 
isomers was achieved on the growth of established 
metastases of both murine and human origins. Most 
importantly, these anti-metastatic effects were achieved 
even at very low concentrations and, different from 
conventional chemotherapy that usually impairs the 
health of the body, both m-tyr and o-tyr seemed to exert 
their anti-tumor effects without displaying any detectable 
toxic-side effects even using doses 20 times higher than 
therapeutic ones.
However, more experiments measuring different 
physiologic variables not only in mice, but also in other 
species such as rats and rabbits, in acute, sub-acute and 
chronic schedules of m-tyr and o-tyr administration, will 
be necessary to demonstrate more accurately their lack of 
toxic-side effects.
Taken together, all the experiments reported in previous 
communications, as well as new experiments, that are 
underway, aimed to explore further the molecular basis 
of the inhibitory effects of m-tyr and o-tyr on tumor cell 
proliferation, could help to develop new and less harmful 
means of managing malignant diseases, especially by 
controlling the growth of metastases after the removal 
of a primary tumor, or after other surgical injuries or 
stressors that have been claimed to promote the escape 
of metastases from dormancy. This is an objective not yet 
achieved by current oncology research.
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